HERON THERAPEUTICS, INC. /DE/

HERON THERAPEUTICS, INC. /DE/ (ticker: HRTX) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of HRTX's SEC filings surfaces 2 active risk signals, including 1 auditor-change signal, and 1 delisting/deregistration signal. HRTX reported no tagged revenue in revenue and -$8.11M for the period ending 2026-03-31, with operating cash flow of -$1.54M. Cash and equivalents stood at $26.12M (up 35.5% year-over-year). Total assets of $246.22M exceed total liabilities of $237.08M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

HRTX Cash Runway

Months-of-runway analysis for HRTX, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on HRTX

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.